Grace Therapeutics (GRCE) Deferred Taxes (2023 - 2026)
Grace Therapeutics (GRCE) posted Deferred Taxes of $870000.0 for Q1 2026, down 80.79% sequentially from $4.5 million in Q1 2025, and down 80.79% YoY from $4.5 million in Q1 2025.
Grace Therapeutics (GRCE) Deferred Taxes (2023 - 2026) Analysis & Trends
Grace Therapeutics has reported Deferred Taxes for 4 years, with the latest figure at $870000.0 in Q1 2026.
- Quarterly Deferred Taxes fell 80.79% year-over-year to $870000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $870000.0 (down 62.93% YoY) and the FY2026 annual result came in at $870000.0, down 62.93% from the prior year.
- Deferred Taxes eased to $870000.0 in Q1 2026 per GRCE's latest filing, from $4.5 million in the prior quarter.
- Over five years, Deferred Taxes peaked at $4.5 million in Q1 2025 and troughed at -$852000.0 in Q3 2024.
- A 4-year average of $556714.3 and a median of -$208000.0 in 2023 frame the typical range for Deferred Taxes.
- The sharpest annual moves came in 2024 and 2025: Deferred Taxes sank 190.87% in 2024, then surged 409.91% in 2025.
- Over 4 years, Deferred Taxes stood at -$208000.0 in 2023, then tumbled by 190.87% to -$605000.0 in 2024, then jumped by 848.43% to $4.5 million in 2025, then plunged by 80.79% to $870000.0 in 2026.
- According to Business Quant data, Deferred Taxes over the past three periods registered $870000.0, $4.5 million, and -$605000.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 2.66 Mn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | - |
| 10 | Grace Therapeutics | 37.82 Mn | 37.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 870,000.00 |
| Mar 31, 2025 | 4.53 Mn |
| Dec 31, 2024 | -605,000.00 |
| Sep 30, 2024 | -852,000.00 |
| Jun 30, 2024 | -724,000.00 |
| Mar 31, 2024 | 888,000.00 |
| Dec 31, 2023 | -208,000.00 |